In the article titled “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab” [1], there were errors, which should be corrected as follows:(i)In Abstract, the term “(DEP)” should be “(PED).”(ii)In Results, “Change of CRT did not reach the significant difference at any time point of the study (M6: 312 ± 91 µm, NS; M12: 312 ± 84 µm, NS; M24: 312 ± 12.3, NS)” should be corrected to “Change of CRT did not reach the significant difference at any time point of the study (M6: 312 ± 14 µm, NS; M12: 313 ± 13.9 µm, NS; M24: 305 ± 76, NS).”(iii)In Table 2, there were errors in the values in the third, fourth, and sixth columns. The corrected table and its description are shown below.
Corrigendum | Open Access
Corrigendum to “Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab”
Received24 Apr 2018
Accepted27 May 2018
Published08 Jul 2018
References
T. H. C. Tran, S. Dumas, and F. Coscas, “Two-year outcome of aflibercept in patients with pigment epithelial detachment due to neovascular age-related macular degeneration (nAMD) refractory to ranibizumab,” Journal of Ophthalmology, vol. 2017, Article ID 8984313, 8 pages, 2017.
View at: Publisher Site | Google Scholar
Copyright
Copyright © 2018 Thi Ha Chau Tran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.